Pharmaceutical companies have been seeing a major change, especially in the United States, which has been facing drug shortages and high drug prices, which have been causing major noise on the global stage, and it has been criticized all over the globe for this. Pharmaceutical companies are being held responsible for this drug crisis.
But the Pharmaceutical companies seem to be turning a blind eye towards these issues, and they continue to expand their research and business by making new deals and partnerships with other similar companies to ensure that they are not affected by the changing trends of the people’s drug habits and medical treatment habits. BioCryst, the United States-based pharmaceutical company, has Announced Partnership With Torii Pharmaceutical in order to expand and commercialize its business in Japan, which is aimed at the prevention of HAE attacks that have been growing and have huge business potential. BioCryst will receive a $22 million upfront payment and is eligible to receive up to an additional $20 million if they are successful and achieve certain things that are discussed in the partnership deal. The company will be aiming at the market for once-daily treatment through oral consumption for the prevention of hereditary angioedema (HAE) attacks.
So with this new deal, the US pharma has declared that it will be expanding its business if the drug prices will be dropping at home and there is no way the pharma is going to suffer a loss as they might as well leave the market completely to avoid what they don’t want to happen.
Tags : Pharmaceutical companies, Japan, BioCryst, US pharma,